Lattice Biologics Ltd.
LBLTF
$0.00
$0.000.00%
OTC PK
| 06/30/2021 | 03/31/2021 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -39.38% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -39.38% | |||
| Cost of Revenue | -- | 18.54% | |||
| Gross Profit | -- | -83.01% | |||
| SG&A Expenses | -92.27% | 3.21% | |||
| Depreciation & Amortization | -- | 58.59% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -96.19% | 14.49% | |||
| Operating Income | 93.37% | -233.39% | |||
| Income Before Tax | 93.37% | -44.70% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 93.37% | -44.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 93.37% | -44.70% | |||
| EBIT | 93.37% | -233.39% | |||
| EBITDA | 112.18% | -335.71% | |||
| EPS Basic | 93.33% | -42.86% | |||
| Normalized Basic EPS | 94.74% | -46.15% | |||
| EPS Diluted | 93.33% | -42.86% | |||
| Normalized Diluted EPS | 94.74% | -46.15% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||